After the Air India flight crashed into a medical campus, the surviving doctors rushed to save lives
Navin Chaudhary had just begun eating his meal when a loud bang startled him. He turned back to see a massive fire taking over the dining area where he and other trainee doctors had assembled for lunch.
Article content
The blaze approaching him, he rushed toward a window and jumped.
Article content
From the ground, looking upwards, the sight of the Air India plane's tail cone hanging from the burning building propelled Chaudhary and fellow medical students into action.
Article content
Article content
He said he felt lucky to survive but knew he had a task at hand. He rushed to the hospital's intensive care unit, where the injured, most of whom had burns, were wheeled in on stretchers.
Article content
'I felt that as a doctor I could save someone's life,' he said. 'I was safe. So I thought, whatever I can do, I should.'
Article content
At least 270 died when the Air India flight crashed into the campus of a medical college in Ahmedabad shortly after takeoff on Thursday. Only one passenger among the 242 aboard survived. At least 29 others on the ground, including five medical students inside the hostel, were also killed.
Article content
Article content
Many believe that the death toll would have been higher if it had not been for the intervention of the trainee doctors and students who emerged from the smouldering hostel and rushed to save their colleagues.
Article content
Akshay Zala, a senior medical student, said the crash felt 'like an earthquake.'
Article content
'I could hardly see anything as thick plumes of smoke and dust engulfed everything. I was barely able to breathe,' he said.
Article content
On Monday, the crash site teemed with excavators and workers clearing the debris. Officials inspected the building in search of clues that could enable the investigators to figure out what led to the tragedy.
Article content
Article content
Barely a kilometer (less than a mile) away, trainee doctors who survived one of India's worst aviation disasters were still working to identify the victims through DNA testing.
Article content
Indian authorities have so far handed over the remains of 47 victims The bodies of 92 others have also been identified through DNA matching and will be transferred to relatives soon.
Article content
College dean Minakshi Parikh said that many of the doctors who pulled their colleagues out of the debris, later that day went back to their duties to save as many lives as they could. 'They did that and that spirit has continued till this moment,' Parikh said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 days ago
- Globe and Mail
Participation in 'The 113th Congress of Japan Society of Aesthetic Surgery,' May 2025
IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical') today announced that a total of 22 representatives, including Yoshiyuki Aikawa, CEO of SBC Medical, and doctors from Shonan Beauty Clinic, a clinic operated under the management support of SBC Medical Group, a consolidated subsidiary, presented their research findings at 'The 113th Congress of Japan Society of Aesthetic Surgery.' Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings Incorporated The Japan Society of Aesthetic Surgery (JSAS), one of Japan's leading professional societies in the field of aesthetic medicine, brings together doctors dedicated to shaping the future of the industry. 'The 113th Congress of Japan Society of Aesthetic Surgery' was held over three days from Wednesday, May 28 to Friday, May 30, 2025, at The Okura Tokyo. Under the theme 'TO BE THE BEST -The Journey of Knowledge Never Ends-,' the congress was chaired in part by Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, who served as Vice Chair of the event. The congress provided a valuable platform for in-depth discussions on international trends and future developments in aesthetic medicine, fostering both academic and clinical insights and promoting global collaboration among experts in the field. Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, served as Vice Chair of this Congress At this congress, a total of 22 representatives from SBC Medical presented their research findings, including Yoshiyuki Aikawa, CEO of SBC Medical, Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group, Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group and Dr. Ayaka Nishikawa, who also served as Vice Chair of the congress. Each speaker shared insights cultivated through daily clinical practice and research in their respective fields of expertise. The event also featured lively discussions on global trends and future developments in aesthetic medicine, providing a valuable opportunity to deepen academic and clinical knowledge and to foster international collaboration. Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group In the rapidly evolving field of aesthetic medicine, the importance of both acquiring and sharing specialized knowledge continues to grow. As technological advancements drive increasingly diverse customer needs, it is essential not only to adopt cutting-edge technologies, but also to maintain a broad and multifaceted perspective. SBC Medical remains committed to contributing to the advancement of the aesthetic medicine industry by actively engaging with academic societies and research institutions, sharing our innovative initiatives, and incorporating the latest global knowledge and technologies into our practice. The 113th Congress of Japan Society of Aesthetic Surgery Venue：The Okura Tokyo Dates：Wednesday, May 28 – Friday, May 30, 2025 Official website： Presentation Topics Chair / Speaker Job Title Title Yoshiyuki Aikawa CEO, SBC Medical Group Holdings 【Special Program/Speaker】 Practical Strategies for Cosmetic Medical Business Management and Marketing 【Special Lecture/Chair】The future of cosmetic medicine and AI Daisuke Nakamura Chief Medical Director of Shonan Beauty Group, Chief of Breast Augmentation at SBC 【Symposium/Speaker】Creating an attractive bust line - Fat injection breast augmentation and breast implant augmentation Kazuhiro Igawa Representative Assistant and Technical Advisor, Shonan Beauty Group 【Symposium/Speaker】Rhinoplasty with an awareness of harmony by considering facial parts as fonts Ayaka Nishikawa Director of Dermatology Department of Shonan Beauty Group 【Luncheon Seminar/Chair/Speaker】The Potential of Microneedle RF：Indications and Practical Combination Treatments in Skin Management 【Invited Lecture/Chair】Unique Treatments and Techniques with injectable Agents A 35 Year Evolution 【Symposium/Speaker】Challenges in Skin Tightening Devices: Insights from Single-Device Treatments with 6.78MHz Monopolar RF 【Sponsored Seminar/Chair】'The WHY'? -Why do we do what we do as an aesthetics injector? 【Presidential Special Program/Speaker】Evaluating the Impact of Different Approaches in Aesthetic Dermatology: A Post-Treatment Study in Identical Twins 【Sponsored Seminar/Speaker】Fine fiber sheet for application after pico-second laser treatment Jiro Kataoka Area Medical Director and Anti-Aging Expert Doctor 【Panel Discussion/Speaker】Deep Plane Facelift for Japanese (Asians) ~My Experience and Ideas~ 【Video Lecture/Chair】Fundamentals and applications of Facelift Surgery: Strategies for Addressing Age-Related Changes Shoko Takahashi Top expert doctor in rejuvenation 【Panel Discussion/Speaker】Patient education and combination treatment to maximize patient satisfaction with thread lifting Hiroaki Takizawa Area Doctor and Director of Jiyugaoka Clinic 【Symposium/Speaker】Revision after double eyelid surgery with sub-brow blepharoplasty Eiko Tanaka Director of Takatsuki Hospital 【Symposium/Chair/Speaker】Innovative Approaches to Improve Labia Majora Laxity: Minimizing Scars in Reduction Surgery Atsushi Hayashi Chief Technical Director 【Panel Discussion/Speaker】Incidence of Post-inflammatory Hyperpigmentation with Picosecond Laser in Patients with Melasma Kanako Misono Slimming Expert Doctor 【Luncheon Seminar/Speaker】Cutting edge of Cryolipolysis: Maximize patient satisfaction with Coolsculpting Soichiro Morikawa Anti-aging treatment expert doctor 【Luncheon Seminar/Speaker】Polynucleotide products and Hyaluronic Acid Filler Poster Presentations Speaker Job Title Title Hiroshi Ohji ー Usefulness of preoperative ultrasound examination in submandibular liposuction. Ayano Okuda Expert doctor in gynecological plastic surgery Diversifying Intimate Area Treatments ~Changes and Current Status of Pubic Hair Removal and Female Genital plastic surgery at Our Clinic~ Go Kanazawa Director of Hiroshima Clinic and Area Doctor for Hiroshima Area Lessons learned from the experience of removing limps formed by fat injection into the lower eyelid Kaito Kuzushima Ginza Clinic Director Top Expert Doctor in Liposuction Asian Buttocks Contouring：witout fat injection 【Evaluated with 3D Vectra】 Aiko Ssasaki Kawagoe Area Area Doctor and Director of Kawagoe Clinic Comparison of eyelid functions before and after completely transconjunctival embedding double eyelid blepharoplasty Yuka Takeda Director of the Esaka Institute The usefulness of next generation needle Nanosoft Microneedles Lifting Effects and Technical Innovations in Full-Face Autologous Fat Grafting Ryuji Tanaka Hokkaido/Tohoku Area General Manager Approach to the Management of Lower Eyelid Hollowness with Skin Laxity Mei Nakayama ー Bilateral symmetrical enlargement within a few months after upper arm liposuction : case report Ayaka Nishikawa Director of Dermatology Department of Shonan Beauty Group Fine fiber sheet for application after pico-second laser treatment Yu Hirata Director of Okayama Clinic and Area Doctor for Okayama Area Study on the direction of fat repositioning in transconjunctival blepharoplasty. Takashi Yamamoto Director of Nagoya Institute Examination of the effects, satisfaction, and risks of orbital fat removal combined with the buried double method Akihiro Yoshida ー Tips to improve the success rate of transconjunctival double eyelid blepharoplasty suture removal About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit Contacts In Asia: SBC Medical Group Holdings Incorporated Hikaru Fukui / Head of Investor Relations E-mail: ir@ In the US: ICR LLC Bill Zima / Managing Partner Email:
CTV News
4 days ago
- CTV News
South Korea ratifies treaty aimed at safeguarding international adoptions
SEOUL, South Korea — After years of delay, South Korea has ratified the Hague Adoption Convention, an international treaty meant to safeguard international adoptions, marking a significant policy shift decades after sending tens of thousands of children to the West through an aggressive but poorly regulated adoption system. The government's announcement Tuesday came as it faces growing pressure to address widespread fraud and abuse that plagued its adoption program, particularly during a heyday in the 1970s and 1980s when the country allowed thousands of children to be adopted every year. Many adoptees have since discovered their records were falsified to portray them as abandoned orphans, carelessly separated or even stolen from their birth families. South Korea's Foreign Ministry and Health and Welfare Ministry, which handles adoption policies, issued a joint statement saying the country submitted the necessary documents to ratify the Hague Convention to the Dutch Foreign Ministry, the treaty's depositary. The treaty, which requires countries to strengthen state oversight and safeguards to ensure international adoptions are legal and ethical, will enter effect in South Korea on Oct. 1. South Korea signed the Hague Convention in 2013, but ratification was delayed by more than 10 years as the country struggled to bring adoptions under centralized government authority, as required by the treaty, after allowing private agencies to control international child placements for decades. 'Going forward, intercountry adoptions will be permitted only when no suitable family can be found in his or her state of origin, and only if deemed to serve the child's best interests through deliberation by the adoption policy committee under the Ministry of Health and Welfare,' the ministries said. The statement said the ratification was a significant step toward safeguarding children's rights and 'establishing an advanced, internationally compliant intercountry adoption system in Korea, reinforcing the government's commitment to upholding state responsibility across the entire adoption process.' A 2023 law also mandates the transfer of all adoption from private agencies to the National Center for the Rights of the Child by July, aiming to centralize processing family search requests from adoptees who have returned to South Korea as adults seeking their roots. International adoptions from South Korea have plummeted in recent years, with only 58 in 2024, according to government data. During the 1980s, South Korea sent more than 6,000 children abroad each year, under a previous military government that viewed adoption as a way to reduce mouths to feed and curry favor with Western nations. Authorities specifically targeted children deemed socially undesirable, including those born to unwed mothers or impoverished families, and granted extensive powers to private adoption agencies to dictate child relinquishments and custody transfers, allowing them to send huge numbers of children abroad quickly. Much of South Korea's recent reforms have focused on abuse prevention, including a 2011 law reinstating judicial oversight of foreign adoptions that led to a significant drop in international placements. But officials are at a loss over how to handle the huge numbers of inaccurate or falsified records accumulated over past decades, which have prevented many adoptees from reconnecting with their birth families or obtaining accurate information about their biological origins. In a landmark report in March, South Korea's Truth and Reconciliation Commission concluded the government bears responsibility for facilitating a foreign adoption program rife with fraud and abuse, driven by efforts to reduce welfare costs and enabled by private agencies that often manipulated children's backgrounds and origins. The commission's findings broadly aligned with a 2024 Associated Press investigation, in collaboration with Frontline (PBS), which detailed how South Korea's government, Western countries and adoption agencies worked in tandem to supply some 200,000 Korean children to parents overseas, despite years of evidence that many were being procured through questionable or outright unscrupulous means. South Korea's government has never acknowledged direct responsibility for issues related to past adoptions and has so far ignored the commission's recommendation to issue an apology. Some adoptees criticized the truth commission's cautiously worded report, arguing it should have more forcefully acknowledged the government's complicity and offered more concrete recommendations for reparations for illegal adoption victims. The commission's investigation deadline expired in May, after it confirmed human rights violations in just 56 of the 367 complaints filed by adoptees since 2022. Kim Tong-hyung, The Associated Press
National Post
4 days ago
- National Post
Biocytogen Responds to Harbour BioMed's Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing
Article content BEIJING — In response to Harbour BioMed's recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement: Article content Biocytogen stands by its core values of independent innovation, respect for intellectual property, and a commitment to fair competition. The RenNano® platform is the result of independent, original R&D, based on Biocytogen's proprietary genome editing technologies. Its technical principles, design strategy, and IP scope are fundamentally different from the patents in dispute. Article content 120 vs. 9 – A Significant Technical Divide of RenNano® Platform Article content ; Article content Biocytogen Will Resolutely Take Legal Actions to Protect Its Rights Article content The RenNano® platform employs a large-fragment knock-in strategy that incorporates over 120 human V genes in situ, enabling a complete and functional human heavy chain antibody repertoire. In stark contrast, Harbour BioMed's HCAb platform introduces only 9 V genes through a small-fragment transgenic approach. This key difference reflects not only divergent technical strategies but also the depth, innovation, and translational potential of Biocytogen's antibody discovery platforms. Article content The decision referenced in Harbour BioMed's PR involves a procedural ruling on jurisdiction only and does not address the substance of the patent infringement case. Furthermore, the CNIPA's affirmation of patent validity is a routine administrative process that does not imply infringement. The underlying lawsuit has not yet entered the trial phase. Article content Biocytogen is currently evaluating all legal options and will resolutely defend its IP rights and scientific reputation. The RenNano® platform has been fully validated and is supported by a robust portfolio of domestic and international patents, clearly documenting its originality and independence. Article content We remain confident in: Article content The technical integrity and legal foundation of the RenNano® platform; The non-infringement of any third-party IP; Our continued leadership in antibody discovery and therapeutic innovation. Article content According to public records, the Chinese patent related to Harbour BioMed's HCAb platform is set to expire on July 22, 2025, further underscoring the short-sighted nature of any speculative claims. Regardless, Biocytogen will continue to uphold its rights, ensure business continuity, and deliver transformative technologies for global partners and patients. Article content Any misleading allegations or speculative narratives will not deter our team from advancing the RenMice® platform series with world-class innovation and delivering on our mission to accelerate therapeutic discovery. Article content Biocytogen's RenNano® Platform and Harbour BioMed's HCAb Platform Article content Biocytogen RenNano® Platform: Uses large-fragment knock-in technology to replace mouse genes with over 120 human V genes in situ, resulting in a full and functional human heavy chain variable region genomic repertoire. Harbour BioMed HCAb Platform: Introduces only 9 V genes using small-fragment transgenic approaches. Article content About Biocytogen Article content Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit Article content Article content Article content Contacts Article content Biocytogen Contacts Article content Article content Antibody platform and assets: Article content BD-Licensing@ Article content Article content Preclinical models and services: Article content Article content
